ImmunityBio Securities Class Action Reminder
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2026
0mins
Should l Buy IBRX?
Source: Globenewswire
- Class Action Notice: Rosen Law Firm reminds investors who purchased ImmunityBio securities between January 19 and March 24, 2026, to apply as lead plaintiffs by May 26, 2026, to participate in the class action and seek compensation.
- Fee Arrangement: Investors joining the class action will incur no upfront costs, as the law firm operates on a contingency fee basis, allowing investors to pursue claims without additional financial burden.
- Case Background: The lawsuit alleges that ImmunityBio made false or misleading statements during the class period, resulting in investor losses when the truth emerged, highlighting significant implications for the company's operations and prospects.
- Law Firm Credentials: Rosen Law Firm is renowned for its success in securities class actions, having recovered over $438 million for investors in 2019 alone, demonstrating its expertise and resource advantages in handling such cases.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.780
Low
5.00
Averages
7.33
High
9.00
Current: 7.780
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Securities Class Action Reminder
- Deadline for Claims: ClaimsFiler reminds investors that those who purchased ImmunityBio shares between January 19 and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- Legal Allegations: ImmunityBio and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could expose investors to significant financial losses.
- FDA Warning Impact: A warning letter from the FDA to CEO Richard Adcock, made public on March 24, 2026, highlighted misleading advertisements for Anktiva, indicating violations of the Federal Food, Drug, and Cosmetic Act and raising public health concerns.
- Stock Price Drop: Following the news, ImmunityBio's stock price fell by 21%, losing $1.98 per share to close at $7.42, reflecting market concerns regarding the company's compliance and future outlook.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio (IBRX) is facing a class action lawsuit for making false statements between January 19 and March 24, 2026, with investors having until May 26, 2026, to seek lead plaintiff status, highlighting significant legal compliance risks for the company.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter accusing ImmunityBio executives of making inaccurate claims about their lead biologic product, Anktiva, on a podcast, resulting in a 21.12% drop in stock price, indicating a severe loss of market confidence in the company's prospects.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for legal support, reflecting investor concerns over corporate governance and transparency, which may influence future investment decisions.
- Legal Consequences: The lawsuit alleges that ImmunityBio made materially misleading statements regarding its business operations, and an unfavorable ruling could lead to substantial financial liabilities, further impacting the company's financial stability and market reputation.
See More
ImmunityBio Shareholder Class Action Filed Over Securities Misrepresentation
- Class Action Initiated: Bernstein Liebhard LLP announces a class action lawsuit on behalf of investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, alleging misrepresentations regarding the capabilities of the company's lead product, ANKTIVA, which may have led to investor losses.
- Legal Procedure Details: Investors wishing to serve as lead plaintiffs must file papers by May 26, 2026, with the lead plaintiff representing other class members in directing the litigation, although non-lead plaintiffs can still share in any recovery without taking action.
- Transparent Fee Structure: The representation operates on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages broader participation from affected shareholders.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times on The National Law Journal’s “Plaintiffs’ Hot List,” demonstrating its expertise and credibility in securities litigation through successful handling of hundreds of class actions.
See More
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiated: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased ImmunityBio, Inc. (NASDAQ:IBRX) securities between January 19, 2026, and March 25, 2026, highlighting concerns over potential misleading actions by the company.
- FDA Warning Letter Exposed: During the class period, CEO Soon-Shiong was accused of overstating the capabilities of the lead product ANKTIVA, particularly after a March 24, 2026, FDA warning letter indicated that promotional communications could mislead investors by claiming ANKTIVA could cure all cancers.
- Significant Stock Drop: Following the FDA warning letter, ImmunityBio's stock fell by 21% on March 24, 2026, losing $1.98 per share and closing at $7.42, reflecting market concerns about the company's future prospects.
- Shareholder Action Guidance: Shareholders can submit applications by May 26, 2026, to serve as lead plaintiffs in the class action, representing other shareholders and emphasizing the importance of corporate governance and executive accountability.
See More
ImmunityBio Faces Federal Securities Class Action
- Lawsuit Deadline: Investors in ImmunityBio must apply to be lead plaintiffs in the federal securities class action by May 26, 2026, as late applications will not be considered by the court, which could significantly impact the company's litigation strategy and future legal standing.
- False Advertising Allegations: The lawsuit alleges that Executive Chairman Patrick Soon-Shiong materially overstated the capabilities of Anktivas, an FDA-approved IL-15 receptor agonist, in public statements, potentially misleading investors about the company's prospects and affecting their investment decisions.
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, stating that its TV ad and podcast were deemed “false or misleading,” which could damage the company's reputation and impact its market performance moving forward.
- Stock Price Plunge: Following the FDA's warning, ImmunityBio's stock price fell from $9.40 per share on March 23, 2026, to $7.41, a decline of 21.2%, reflecting a significant loss of market confidence in the company's future, which may hinder its financing and operational capabilities.
See More
Securities Fraud Class Action Filed Against ImmunityBio, Inc.
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio, Inc. (NASDAQ:IBRX) on behalf of investors who purchased shares between January 19, 2026, and March 24, 2026, highlighting serious concerns regarding the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, which misled investors about the company's prospects and could negatively impact its stock price and market trust.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price, raising investor concerns about corporate governance and compliance.
- Investor Action Recommendations: Investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent all affected investors, indicating a focus on the company's future legal and financial responsibilities.
See More
ImmunityBio Securities Class Action Reminder
- Deadline for Claims: ClaimsFiler reminds investors that those who purchased ImmunityBio shares between January 19 and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit against the company.
- Legal Allegations: ImmunityBio and certain executives are accused of failing to disclose material information during the class period, violating federal securities laws, which could expose investors to significant financial losses.
- FDA Warning Impact: A warning letter from the FDA to CEO Richard Adcock, made public on March 24, 2026, highlighted misleading advertisements for Anktiva, indicating violations of the Federal Food, Drug, and Cosmetic Act and raising public health concerns.
- Stock Price Drop: Following the news, ImmunityBio's stock price fell by 21%, losing $1.98 per share to close at $7.42, reflecting market concerns regarding the company's compliance and future outlook.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Background: ImmunityBio (IBRX) is facing a class action lawsuit for making false statements between January 19 and March 24, 2026, with investors having until May 26, 2026, to seek lead plaintiff status, highlighting significant legal compliance risks for the company.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter accusing ImmunityBio executives of making inaccurate claims about their lead biologic product, Anktiva, on a podcast, resulting in a 21.12% drop in stock price, indicating a severe loss of market confidence in the company's prospects.
- Investor Action: Affected investors are encouraged to contact Kessler Topaz Meltzer & Check, LLP for legal support, reflecting investor concerns over corporate governance and transparency, which may influence future investment decisions.
- Legal Consequences: The lawsuit alleges that ImmunityBio made materially misleading statements regarding its business operations, and an unfavorable ruling could lead to substantial financial liabilities, further impacting the company's financial stability and market reputation.
See More
ImmunityBio Shareholder Class Action Filed Over Securities Misrepresentation
- Class Action Initiated: Bernstein Liebhard LLP announces a class action lawsuit on behalf of investors who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19 and March 24, 2026, alleging misrepresentations regarding the capabilities of the company's lead product, ANKTIVA, which may have led to investor losses.
- Legal Procedure Details: Investors wishing to serve as lead plaintiffs must file papers by May 26, 2026, with the lead plaintiff representing other class members in directing the litigation, although non-lead plaintiffs can still share in any recovery without taking action.
- Transparent Fee Structure: The representation operates on a contingency fee basis, meaning shareholders incur no fees or expenses, which reduces the financial burden on investors and encourages broader participation from affected shareholders.
- Law Firm Background: Bernstein Liebhard LLP has recovered over $3.5 billion for clients since 1993 and has been recognized multiple times on The National Law Journal’s “Plaintiffs’ Hot List,” demonstrating its expertise and credibility in securities litigation through successful handling of hundreds of class actions.
See More
ImmunityBio Faces Class Action Lawsuit Over Misleading Claims
- Class Action Initiated: Robbins LLP reminds shareholders of a class action filed on behalf of investors who purchased ImmunityBio, Inc. (NASDAQ:IBRX) securities between January 19, 2026, and March 25, 2026, highlighting concerns over potential misleading actions by the company.
- FDA Warning Letter Exposed: During the class period, CEO Soon-Shiong was accused of overstating the capabilities of the lead product ANKTIVA, particularly after a March 24, 2026, FDA warning letter indicated that promotional communications could mislead investors by claiming ANKTIVA could cure all cancers.
- Significant Stock Drop: Following the FDA warning letter, ImmunityBio's stock fell by 21% on March 24, 2026, losing $1.98 per share and closing at $7.42, reflecting market concerns about the company's future prospects.
- Shareholder Action Guidance: Shareholders can submit applications by May 26, 2026, to serve as lead plaintiffs in the class action, representing other shareholders and emphasizing the importance of corporate governance and executive accountability.
See More
ImmunityBio Faces Federal Securities Class Action
- Lawsuit Deadline: Investors in ImmunityBio must apply to be lead plaintiffs in the federal securities class action by May 26, 2026, as late applications will not be considered by the court, which could significantly impact the company's litigation strategy and future legal standing.
- False Advertising Allegations: The lawsuit alleges that Executive Chairman Patrick Soon-Shiong materially overstated the capabilities of Anktivas, an FDA-approved IL-15 receptor agonist, in public statements, potentially misleading investors about the company's prospects and affecting their investment decisions.
- FDA Warning Letter: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, stating that its TV ad and podcast were deemed “false or misleading,” which could damage the company's reputation and impact its market performance moving forward.
- Stock Price Plunge: Following the FDA's warning, ImmunityBio's stock price fell from $9.40 per share on March 23, 2026, to $7.41, a decline of 21.2%, reflecting a significant loss of market confidence in the company's future, which may hinder its financing and operational capabilities.
See More
Securities Fraud Class Action Filed Against ImmunityBio, Inc.
- Lawsuit Background: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio, Inc. (NASDAQ:IBRX) on behalf of investors who purchased shares between January 19, 2026, and March 24, 2026, highlighting serious concerns regarding the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially false and misleading statements during this period, particularly regarding the capabilities of its cancer vaccine Anktiva, which misled investors about the company's prospects and could negatively impact its stock price and market trust.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price, raising investor concerns about corporate governance and compliance.
- Investor Action Recommendations: Investors are encouraged to apply for lead plaintiff status by May 26, 2026, to represent all affected investors, indicating a focus on the company's future legal and financial responsibilities.
See More
